Localisation and Function of the Endocannabinoid System in the Human Ovary by El-Talatini, Mona R. et al.
Localisation and Function of the Endocannabinoid
System in the Human Ovary
Mona R. El-Talatini
1, Anthony H. Taylor
1, Janine C. Elson
2, Laurence Brown
3, Allan C. Davidson
2, Justin C.
Konje
1*
1Endocannabinoid Research Group, Reproductive Sciences Section, Department of Cancer Studies & Molecular Medicine, University of Leicester, Leicester, United
Kingdom, 2Assisted Conception Unit, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, 3Department of Pathology,
Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
Abstract
Background: Although anandamide (AEA) had been measured in human follicular fluid and is suggested to play a role in
ovarian follicle and oocyte maturity, its exact source and role in the human ovary remains unclear.
Methods and Findings: Immunohistochemical examination of normal human ovaries indicated that the endocannabinoid
system was present and widely expressed in the ovarian medulla and cortex with more intense cannabinoid receptor 2
(CB2) than CB1 immunoreactivity in the granulosa cells of primordial, primary, secondary, tertiary follicles, corpus luteum
and corpus albicans. The enzymes, fatty acid amide hydrolase (FAAH) and N-acyclphosphatidylethanolamine-phospholipase
D (NAPE-PLD), were only found in growing secondary and tertiary follicles and corpora lutea and albicantes. The follicular
fluid (FF) AEA concentrations of 260 FF samples, taken from 37 infertile women undergoing controlled ovarian
hyperstimulation for in vitro fertilisation and intracytoplasmic sperm injection with embryo transfer, were correlated with
ovarian follicle size (P=0.03). Significantly higher FF AEA concentrations were also observed in mature follicles
(1.4360.04 nM; mean6SEM) compared to immature follicles (1.2660.06 nM), P=0.0142 and from follicles containing
morphologically assessed mature oocytes (1.5660.11 nM) compared to that containing immature oocytes (0.9960.09 nM),
P=0.0011. ROC analysis indicated that a FF AEA level of 1.09 nM could discriminate between mature and immature oocytes
with 72.2% sensitivity and 77.14% specificity, whilst plasma AEA levels and FF AEA levels on oocyte retrieval day were not
significantly different (P=0.23).
Conclusions: These data suggest that AEA is produced in the ovary, is under hormonal control and plays a role in
folliculogenesis, preovulatory follicle maturation, oocyte maturity and ovulation.
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Introduction
Endocannabinoids (endogenous cannabinoids) are unsaturated
fatty acid derivatives widely distributed in the human body [1].
Anandamide (AEA), the most studied endocannabinoid, mimics
some of the central and peripheral effects of D
9 - tetrahydrocan-
nabinol (D
9-THC), the psychoactive component of marijuana [2].
AEA, an ethanolamine amide of arachidonic acid, the precursor of
prostaglandins and leukotrienes [3] is synthesised on demand
through the sequential actions of N-acyltransferase (NAT) and a
molecule-specific enzyme N-acyclphosphatidylethanolamine-phos-
pholipase D (NAPE-PLD) [4]. AEA binds to and activates
cannabinoid receptors of which there are two main isoforms,
cannabinoid receptor 1 (CB1) and CB2 [5]. In the human, CB1 is
considered to be the main receptor in the central nervous system
[6] and is expressed in many other peripheral tissues such as the
adrenal gland, ovaries, uterus, testis, prostate [5], and placenta [7].
In contrast, CB2, which is not expressed in the brain except in
conditions of extreme stress, is mainly found in immune-based
tissues [8] such as the spleen, tonsils, thymus, bone marrow, B-
cells, natural killer cells, monocytes, polymorphic mononuclear
cells, neutrophils and T8- and T4-postive cells [5] and more
recently in the 1
st trimester trophoblast [9]. On binding and
internalisation, AEA is degraded to arachidonic acid and
ethanolamine by the microsomal enzyme fatty acid amide
hydrolase (FAAH) [10]. FAAH and NAPE-PLD are considered
to be the main regulators of AEA in target tissues often referred to
as ‘anandamide tone’ [11]. The ligands (endocannabinoids),
receptors and enzymes as a group constitute the main components
of the endocannabinoid system.
Our knowledge about the effect of cannabinoids on the ovary
comes from studies in animals [12] and marijuana users [13].
Studies in the in-vitro rat ovary model demonstrated that D
9-THC
exerts a direct inhibitory effect on folliculogenesis [12] and
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4579ovulation [14] whereas it causes anovulation in rats [15], rabbits
and rhesus monkeys [16] as a result of LH surge disruption [17].
The effects of cannabis and THC on the human ovary have been
studied and shown to be inconsistent [18] mainly due to the
development of tolerance among chronic users [18] and the timing
of administration of cannabis in relation to the phases of the
menstrual cycle [13]. While in some studies, chronic cannabis
smokers appeared to have normal menses after intensive smoking
Figure 1. Immunohistochemical staining for CB1, CB2, FAAH and NAPE-PLD on control tissues. Images on the left side of the panel
represent the negative control (IgG/serum) and images on the right side of the panel are sections incubated with specific antibodies/antisera. The
tissues used in a–f are human fetal membranes whereas g and h are human endometrium. CB1, CB2 and FAAH Immunoreactivity was observed in the
amnion (Am), chorion (Ch) and decidua (Dec) of term fetal membranes, whilst NAPE-PLD immunoreactivity was observed mainly in the endometrial
glands (Gl) with sparse staining in endometrial stroma (S). The images are representatives from at least six samples and were taken at 2006
magnification. Bar=50 mm.
doi:10.1371/journal.pone.0004579.g001
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short luteal phase. Nevertheless, a direct adverse effect on the
ovary were clearly observed as cannabis users were at a higher risk
of primary infertility due to anovulation [19], and even when these
women had IVF treatment, they produced poor quality oocytes
and lower pregnancy rates compared to non-users [20].
AEA has been demonstrated in ovarian follicular fluids at the
time of oocyte retrieval in IVF cycles suggesting that it may play a
role in ovarian follicle or oocyte maturity [21,22]. However, the
source of AEA in the follicular fluid and its possible role within the
ovary remains poorly understood. Therefore, our study aimed to
localise the endocannabinoid system in the ovary and to
investigate whether follicular fluid or plasma AEA levels are
related to physiologically important ovarian events such as
folliculogenesis, the size and maturity of preovulatory follicle,
oocyte maturity, and ovulation.
Materials and Methods
Each volunteer signed an informed written consent prior to
entry in to the study which was approved by the Leicestershire and
Rutland Research Ethics Committee.
Our study was in 2 parts; the first was mainly to localise the
endocannabinoid system in the ovary using immunohistochemis-
try, and the second to investigate the role of AEA in ovarian
follicles in relation to folliculogenesis, follicle size and oocyte
maturity.
Subjects
For the immunohistochemical studies, 12 ovarian tissue blocks
were collected prospectively from women with regular (cycle
length 28–32 days) menstrual cycles having a hysterectomy and
bilateral salpingo-oophorectomy for benign pathology such as;
heavy periods, benign ovarian cyst or prophylactic oophorectomy
for family history of ovarian cancer. The woman who had a family
history of ovarian cancer was not a carrier of the BRCA1 gene.
None of the volunteers had been on any medication for at least
one month prior to surgery. The ovaries were confirmed by a
gynaecological pathologist to be normal. Control tissues including
fetal membranes (for CB1, CB2 and FAAH) and secretory phase
endometrium (for NAPE-PLD) were obtained from women
undergoing elective Caesarean section at term [9] and hysterec-
tomy for benign conditions such as myoma or dysfunctional
uterine bleeding [23], respectively. All tissues were fixed in 10%
neutral buffered formalin for 4 days before being embedded in
paraffin wax.
For the assessment of follicular fluid AEA concentrations and
the possible role of AEA in ovarian physiology, a total of 37
women undergoing ovarian stimulation for in vitro fertilisation
(IVF) and intracytoplasmic sperm injection (ICSI) with embryo
transfer (ET) between July 2007 and December 2007 were
recruited into the study at the Assisted Conception Unit of the
Leicester Royal Infirmary Hospital. All women were healthy and
had no other medical disorders, had not used cannabis in the last
10 years and had a basal FSH of #10 IU/l in the period prior to
starting IVF/ICSI-ET. Eight percent of the volunteers smoked the
remainder did not.
Controlled ovarian stimulation protocol, follicular fluid
sampling and oocyte retrieval
Ovarian stimulation was performed using a long protocol, with
pituitary down-regulation with the gonodatrophin releasing
hormone (GnRH) agonist Supercur (Aventis Pharma Ltd, Kent,
UK) commenced in the mid luteal phase of the previous cycle and
continued until ovulatory human chorionic gonadotrophin (hCG)
was given [24]. Stimulation was initiated with either human
menopausal gonadotrophin (hMG) Menopur (Ferring, Langley,
UK) or recombinant follicle stimulating hormone (rFSH) Puregon
(Organon Laboratories Ltd, Cambridge, UK) or a combination of
rFSH and hMG [25] once there was no sonographic evidence of
ovarian follicular activity and serum estradiol levels were below
200 pmol/L. The dosage was based on the patient’s age, BMI and
early follicular phase serum FSH levels [26]. Follicular maturation
was assessed by serial (every 2–3 days) transvaginal ultrasound
scan and serum estradiol measurements [27]. hCG 10,000 IU
(Pregnyl; Organon Laboratories Ltd, Cambridge, UK) was
administered subcutaneously to induce final oocyte maturation
when at least 4 follicles measuring at least 17 mm in diameter
combined with an endometrial thickness of 8 mm were observed.
Thirty-six hours after hCG administration, oocyte retrieval was
performed transvaginally under ultrasound guidance and intrave-
nous sedation with a combination of Propofol (Propoven 1%;
Fresenius Kabi Ltd, Cheshire, UK), Alfentanil hydrochloride
(Rapifen; Janssen-Cilag Ltd, Buckinghamshire, UK) and Mid-
azolam (Hypnovel; Roche, Hertfordshire, UK). All the identified
follicles were aspirated until the follicle wall collapsed. Prior to the
administration of sedation, 4 ml of blood was collected into an
EDTA tube for AEA assay. The aspirated fluid was then examined
under a low power stereomicroscope (Nikon SM200) by an
experienced embryologist for the presence of oocytes. The corona-
cumulus-oocyte complex was identified, and removed with a
Pasteur glass pipette (Poulten & Graf Ltd, Barking, UK). The
follicular fluid from each follicle was thereafter collected into
Kimble Scintillation vials for AEA measurements.
Measurement of Plasma and follicular fluid AEA
concentrations
Blood and follicular fluid samples were processed within two
hours of collection. Plasma and follicular fluid AEA concentrations
were quantified using the Ultra Performance Liquid Chromatog-
raphy-Mass Spectrometry (UPLC-MS/MS) method which we
previously described [28]. AEA measurements were only made
form samples that were at least 1 ml in volume as our extraction
method was not valid for lower volumes.
Assessment of ovarian follicle size, oocyte maturity and
embryo quality
The follicle size was determined by measuring the volume of the
fluid aspirated [29] obtained from individual follicles with Falcon
Figure 2. Immunohistochemical staining for CB1 and CB2 receptors. Images on the left side of the panel represent the negative control (IgG)
and images in the middle are for CB1 on the right are for CB2. Images a, b and c are primordial follicle; d, e and f are primary follicles; g, h and i are
secondary follicles; j, k and l are low power images of tertiary follicles; m, n an o are high power images of tertiary follicles, p, q and r are corpus
luteum, r, s and t are images of the corpus albicans. Granulosa cells (G), theca cell layers (Th), the oocyte (O) and follicular fluid (ff) demonstrated CB1
and CB2 immunoreactivity as did lutein-granulosa cells of the corpus luteum (CL) and corpus albicans (CL), and septa (S) between lobes of these
postovulatory bodies. The images are representatives from at least two structures and taken at 506, 2006 or 4006 magnification. Bar=50 mm.
Ovarian follicles were classified as primordial, primary, secondary, tertiary, corpus luteum, and corpus albicans [43].
doi:10.1371/journal.pone.0004579.g002
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Plymouth, UK). Standard techniques for ICSI and In -vitro
insemination and culture were followed [30]. Only the oocytes
from patients having ICSI were assessed for maturity since oocytes
from IVF are not routinely assessed for maturity. Oocytes were
mechanically cleaned from their surrounding cumulus cells by
aspiration through a plastic Stripper Tip (,125 ml inner diameter;
MidAtlantic Diagnostics, Berlin, Germany). All the oocytes were
examined by an embryologist with an inverted microscope
(Olympus I 670) at a magnification of 6200 and those with a
polar body were selected for micromanipulation. Oocyte maturity
was based on morphological assessment [31] where (a) germinal
vesicle (GV) stage represented very immature oocyte with a
germinal vesicle present, (b) metaphase I (MI) stage oocytes were
still immature but the germinal vesicle had disappeared and the
first polar body had not been extruded and (c) metaphase II (MII)
oocytes were mature and the first polar body was present.
Embryo quality was assessed during the second and third day
[32] of culture and was defined by the number, shape and size of
blastomeres, presence of vacuoles and the grade of fragmentation.
The scale was from 1 to 4, where 1 is the best and 4 the poorest
quality. Grade 1 embryos have blastomeres which are even and
spherical in shape and fill the volume of zona and there is no
fragmentation; Grade 2 embryos have blastomeres which are
slightly uneven or irregularly shaped and there is up to 10%
fragmentation; Grade 3 embryos exhibit fragmentation of not
more than 50% of the blastomeres, and grade 4 embryos have
gross fragmentation of more than 50% of the blastomeres.
Immunolocalisation of CB1,C B 2 and FAAH
The CB1 and CB2 rabbit polyclonal antibodies (Sigma-Aldrich
Ltd., Poole Dorset, UK) were used at 1:500 and 1:250 dilutions,
respectively with rabbit IgG (Dako, Glostrup, Denmark) diluted to
the same concentration as the negative control. The FAAH rabbit
immunised serum (Alpha Diagnostics International, San Antonio,
TX) was used at a 1:2000 dilution with normal rabbit serum
(DAKO) diluted to the same concentration as control.
Tissues sections (5 mm) were mounted onto silanized glass
microscope slides and dried for 7 days at 37uC prior to use. Slides
were de-waxed in xylene three times for 3 min and re-hydrated in
graded alcohol for 3 min followed by incubation in distilled water
for 3 min. Microwave antigen retrieval was performed for CB1
and CB2 only by incubating the slides in 10 mM citric acid buffer
(pH 6.0) heated at 700 watts for 10 min [33]. Endogenous
peroxidase activity was then blocked by incubation in 6% H2O2 in
water for 10 min. Blocking of non-specific protein binding sites
was performed by incubation in 10% normal goat serum for
10 min at room temperature. Endogenous avidin and biotin sites
were blocked using the Avidin-Biotin Blocking Kit (Vector
Laboratories) as recommended by the manufacturer. Primary
antibodies diluted in tris-buffered saline (TBS; 0.5 M Trizma,
1.5 M NaCl, 2 mM MgCl2, pH 7.6; 100 ml/slide) were added and
the slides were incubated in a humid chamber overnight at 4uC.
Slides were then washed in TBA [Tris-buffered saline containing
0.1% bovine serum albumin (Fraction V; Sigma-Aldrich Ltd.)] for
30 min. After washing the slides for 30 min in TBS, biotinylated
goat anti-rabbit antibody (Vector Laboratories) diluted to 1:400 in
TBA was applied for 30 min at room temperature. After an
additional wash in TBS, and ABC Elite reagent was applied
according to the manufacturer’s detailed instructions. After
additional washing in TBS for 20 min, DAB was added to each
slide (100 ml/slide) for 5 min. Slides were then washed in distilled
water for 5 min before counterstaining in Mayer’s haematoxylin
for 15 seconds. After washing in running tap water for 5 min,
slides were dehydrated in graded alcohols, cleared in xylene twice
for 6 min before mounting with DPX mounting medium (BDH
Poole, Dorset).
Immunolocalisation of NAPE-PLD
NAPE-PLD immunohistochemistry was performed according
to the manufacturer’s instructions (ABIN110270; Cayman Chem-
icals, Ann Arbor, MI). Briefly after de-waxing and rehydration to
water, endogenous peroxidase activity was blocked by incubation
in 3% H2O2 in ice-cold water for 15 min and non-specific protein
binding sites blocked with 5% normal goat serum in TBS (TBS;
0.5 M Trizma, 1.5 M NaCl, pH 7.4; 100 ml/slide) for 30 min at
room temperature. Primary antibodies diluted in TBS (1:200) were
added and the slides were incubated in a humid chamber
overnight at room temperature. After washing in TBS containing
0.1% Tween 20 (TBS-T; Sigma-Aldrich Ltd.) three times for
5 min with buffer changes, biotinylated goat anti-rabbit antibody
(Dako; Glostrup, Denmark) diluted to 1:400 in TBS was applied
for 30 min at room temperature. After an additional wash in TBS-
T, ABC Elite reagent (Vector Laboratories) was applied and the
slides washed again. Immunoreactivity was visualised with 3,39-
diaminobenzidine for 5 min and lightly counterstained with
Mayer’s haematoxylin. After washing in running tap water for
5 min, slides were dehydrated in graded alcohols, cleared in xylene
twice for 6 min before mounting with DPX mounting medium
(BDH Poole, Dorset).
Photomicrographs were taken on an Axioplan transmission
microscope equipped with a Sony DXC-151P analogue camera
connected to a computer running Axiovision image capture and
processing software (Axiovison version 4.4, Carl Zeiss Ltd.,
Welwyn Garden City, Hertfordshire, UK). Images were captured
at 506, 2006or 4006magnification in the presence of daylight
and medium value neutral density filters with the lamp set at
6400K. Image backgrounds were colour corrected to neutral grey
with the use of ColorPilot software (version 4.62; www.colorpilot.
com). Immunohistochemical staining was subjectively scored as
absent (2), present (+), or intense staining (++).
Statistics
Demographic and cycle characteristic data are expressed as
mean6SD (range) or median where appropriate. Follicular fluid
and plasma AEA levels are expressed as mean6SEM. Means were
compared using the unpaired Student’s t-test and P,0.05 was
considered statistically significant. For correlations between follicle
size and follicular fluid AEA concentrations Spearman correlation
test was used.
Figure 3. Immunohistochemical staining for FAAH. Images on the left side of the panel represent the negative control (non-immune rabbit
serum and images on the right are for FAAH. Images a and b are primordial follicle; c and d are primary follicles; e and f are secondary follicles; g and h
are low power images of tertiary follicles; i and j are high power images of tertiary follicles, k and l are corpus luteum, and m and n are images of the
corpus albicans. Granulosa cells (G), theca cell layers (Th), the oocyte (O) and follicular fluid (ff) demonstrated FAAH immunoreactivity as did lutein-
granulosa cells of the corpus luteum (CL) and corpus albicans (CL), and septa (S). There was a gradation of staining in the granulosa cells of the
tertiary follicle with greatest intensity in the mural cells (panel j). The images are representatives from at least two structures and taken at 506, 2006
or 4006magnification. Bar=50 mm.
doi:10.1371/journal.pone.0004579.g003
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The mean age of the 12 volunteers from whom ovarian sections
were obtained was 41.862.8 (range 39–45 years). The indications
for removal of the ovaries were menorrhagia (6 women), benign
ovarian cyst (5 women) and prophylactic oophorectomy for a
family history of ovarian cancer (1 woman).
Immunohistochemistry
Specificities for each of the antibodies used in these studies using
control tissues are shown in Figure 1, using term fetal membranes
for CB1, CB2 and FAAH and secretory phase endometrium for
NAPE-PLD. Immunohistochemical analysis of the ovarian tissues
for immunoreactive CB1, CB2, FAAH and NAPE-PLD revealed a
widespread pattern of immunostaining in the ovarian cortex and
medulla (Figures 2, 3, 4, and Table 1). The immunoreactivity for
CB1 was observed in the medulla and the cortex. With regard to
the follicles CB1 was localised in primordial, primary, secondary
and tertiary follicles but mainly in the granulosa and theca cells of
the secondary and tertiary follicles. Immunostaining was observed
in the oocytes of these follicles and increased in the granulosa cells
of the tertiary follicle and was observed in the corpora lutea and
corpora albicantes (Figure 2). Likewise, CB2 (Figure 2o) was
expressed in a similar manner as CB1 (Figure 2n) except the CB2
staining was more intense in the ovarian follicles in comparison to
CB1 and more intense in the oocytes and granulosa cells in
comparison to the theca cells (Figure 2c, 2f, 2i and 2o). However,
FAAH immunostaining was not observed in the granulosa cells or
the oocytes of primordial, primary, secondary or tertiary follicles
but was expressed in the theca cells of secondary and tertiary
follicles, and luteinized granulosa cells of the corpus luteum and
corpus albicans (Figure 3l and 3n). NAPE-PLD immunostaining
was occasionally observed in the oocytes of primordial follicles, but
not in the granulosa cells of primordial or primary follicles
(Figure 4). NAPE-PLD immunostaining was also absent from the
oocytes of other types of follicles. However, NAPE-PLD was
clearly expressed in the granulosa and theca cells of the secondary
and tertiary follicles and corpus luteum, corpus albicans, and
medulla (Figure 4). The intensity of immunostaining of NAPE-
PLD in the corpus albicans (Figure 4n) appeared to be of a lower
intensity when compared to that of FAAH staining in corpus
albicans (Figure 3n).
IVF/ICSI-ET patients and follicular AEA measurements
A total of 37 women undergoing IVF/ICSI-ET were recruited
in to this part of the study, their mean age and BMI were
33.2865.08 years, 24.2562.68 Kg/m
2, respectively. Tables 2 and
3 show the demographic characteristics of these women and the
medications used for controlled ovarian hyperstimulation.
A total of 260 follicles from these women were studied, of which
193 contained at least 1 ml of follicular fluid; their volume having
been accurately measured. There was a significant (P=0.035)
positive correlation between follicular size and follicular fluid AEA
concentration (Figure 5). The measured AEA concentration
Figure 4. Immunohistochemical staining for NAPE-PLD. Images in the left side of the panel represent the negative control (rabbit IgG) and
images on the right are for NAPE-PLD. Images a, and b are primordial follicles, c and d are primary follicles, e and f are secondary follicles; g and h are
low power images of tertiary follicles, i and j are high power images of tertiary follicles, k and i are images of corpus luteum, and m and n are images
of corpus albicans. Granulosa cells (G), theca cell layers (Th), the oocyte (O) and follicular fluid (ff) demonstrated NAPE-PLD immunoreactivity as did
lutein-granulosa cells of the corpus luteum (CL) and corpus albicans (CL) and septa (S). The images are representative from at least two structures and
taken at 506, 2006, or 4006magnification. Bar=50 mm.
doi:10.1371/journal.pone.0004579.g004
Table 1. Immunohistochemistry localisation of the various
components of the endocannabinoid system in the human
ovary.
Structure Cell type CB1 CB2 FAAH NAPE-PLD
Primordial Follicle oocyte ++ + 22 /+
granulosa ++ + 2 +
Primary Follicle oocyte ++ + 22
granulosa ++22
Secondary Follicle oocyte ++ + 22
granulosa +++ + +
theca + + ++ ++
Tertiary Follicle oocyte 2 ++ 22
granulosa ++ + 2/+ 2/++
theca + + ++ ++
Corpus luteum ++ + + ++
Corpus albicans ++2 +
Scoring system (2)=staining absent; (+)=staining visible; (++)=strong
staining.
doi:10.1371/journal.pone.0004579.t001
Table 2. Characteristics of the 37 volunteers undergoing IVF/
ICSI-ET.
Category Sub-Category Mean/ number SD Range
Age (years) 33.28 5.08 23–42
BMI (Kg/m
2) 24.25 2.68 19.5–30
Infertility period (years) 3.86 2.45 1–14
Type of infertility: Primary 26
Secondary 11
Infertility cause
Male factor 16
Unexplained 11
Tubal 7
Endometriosis 1
PCOD+male 1
tubal+male 1
Treatment: ICSI 20
IVF 15
ICSI+IVF 2
Basal hormones:
Basal FSH (IU/l) 5.69 1.68 2.5–9.9
Basal LH (IU/l) 4.81 1.72 2–10
SD=standard deviation; Range=minimum to maximum values; BMI=body
mass index; PCOD=polycystic ovarian syndrome; IVF=in-vitro fertilization;
ICSI=intracytoplasmic sperm injection; FSH=follicle stimulating hormone;
LH=luteinizing hormone.
doi:10.1371/journal.pone.0004579.t002
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which eggs were retrieved was significantly higher than that
(1.2660.06 nM) in the follicular fluid of 88 follicles where oocytes
were not retrieved (P=0.014).
A total of 53 oocytes were retrieved from those undergoing ICSI
and 35 of these were mature and 18 immature. The mean
follicular fluid AEA concentrations (1.5660.11 nM) in follicles
with mature oocytes was significantly (P=0.001) higher than that
(0.9960.09 nM) of the immature oocytes (Figure 6a). Further-
more, ROC curve analysis revealed that a cut-off level for
follicular AEA concentrations that identified a mature oocyte, was
1.09 nM with an area under the curve of 0.7660.07 (P=0.001)
with a sensitivity of 72.2% and a specificity of 77.14% (Figure 6b).
After sperm injection and incubation, of the 35 mature oocytes,
21(60%) were fertilised; and 13 of these (61.9%) were good and 8
were poor quality embryos on the day of embryo transfer (48 to
72 hours later). The mean AEA concentrations in follicles that
produced good (1.4960.21 nM), and in those producing poor
(1.4860.19 nM) quality embryos were similar (P=0.99).
There was no significant difference (P=0.23) between the mean
plasma AEA concentrations (1.5260.07 nM) of the 37 women on
the day of oocyte retrieval and the mean follicular fluid
concentrations (1.4260.05 nM) from all the follicles for each
woman. In addition, the mean plasma AEA concentrations on the
day of oocyte retrieval were similar (P=0.27) to the values we
previously reported in plasma AEA (1.3360.16 nM) at the time of
ovulation in natural cycles [34].
Discussion
The endocannabinoid system in the human ovary has very
rarely been investigated, and our recent observations that plasma
anandamide concentrations increase at the time of ovulation in the
natural menstrual cycle prompted us to look at the ovary in more
detail [34]. Although Scheul et al. [21] quantified anandamide and
some of its congeners in follicular fluid, there was sparse evidence
in the literature that either confirmed this observation or explained
the exact function of AEA in the human ovary. Therefore, our
current study was designed to localise the endocannabinoid system
in the human ovary and to examine if there was a role for AEA in
relation to the physiologically vital processes that occur in the
ovary, such as folliculogenesis, preovulatory follicle maturation or
oocyte maturity.
To the best of our knowledge, this is the first time that the entire
endocannabinoid system; i.e. the ligand, the receptors and the
enzymes responsible for AEA regulation have been localised in the
human ovary. The immunostaining showed widespread expression
of CB1 and CB2 receptors in the medulla and cortex of the ovary.
In the cortex the receptors were expressed in the granulosa cells of
primordial, primary, secondary and tertiary follicles and in the
theca cells of secondary and tertiary follicles. Immunostaining for
both receptors was also observed in the corpus luteum and corpus
albicans. In general, CB2 immunostaining was more intense than
CB1 in the ovary, but interestingly, oocytes of follicles at all stages
of development did not show positive expression of CB1 or CB2
except the oocytes of tertiary follicles, which expressed the CB2
receptor. These data suggest that the follicles and corpora are all
likely to respond to AEA, but oocytes may not respond to AEA
Table 3. Details of the ovulation stimulation regimen, number of oocytes collected per cycle and number of embryos on the day
of embryo transfer.
Mean/ number SD Median Range
Duration of stimulation (days) 11.55 1.38 12 9–15
Dose of Puregon (rFSH) IU/L 2251.08 1478.99 2025 675–6450
Dose of Menopur (hMG) IUL 3967.50 1895.86 3600 1950–7650
Dose of Puregon IU/L+Menopur IU/L 3425+1850 1242.22+482.18 3300+1650 2250–5725+1500–2400
Number of women stimulated by Puregon (rFSH) 25
Number of women stimulated by Menopur (hMG) 9
Number of women stimulated by hMG+rFSH 3
Number of follicles aspirated per woman 16.41 6.89 15 2–29
Number of oocytes collected per woman 11.37 5.07 11 1–23
Total number of embryos per woman on the day of embryo transfer 5.30 3.09 5.50 1–14
Number of good quality embryos on the day of transfer 4.08 3.24 4 1–14
hMG=human menopausal gonadotrophins; rFSH=recombinant follicle stimulating hormone.
doi:10.1371/journal.pone.0004579.t003
Figure 5. Spearman correlation between follicular fluid AEA
concentration and follicle size. A positive correlation between the
size of preovulatory follicle (in ml) and the concentrations of follicular
fluids AEA from IVF/ICSI patients is shown. Follicular fluids from 193
follicles were analysed, R=0.1304; P=0.03.
doi:10.1371/journal.pone.0004579.g005
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us to suggest that AEA may be involved in oocyte maturity,
through the actions of the CB2 receptor. However, it is
acknowledged that immunohistochemistry as the only approach
investigating the endocannabinoid system in the ovary is limited,
and that studies with other techniques, e. g. in vitro functional
studies, if feasible, would be more comprehensive.
FAAH, the enzyme responsible for the degradation of AEA, was
expressed only in theca cells of secondary and tertiary follicles, the
corpus luteum and corpus albicans. These data suggest that AEA
is acting in an autocrine manner on the granulosa cell to stimulate
unknown phenotypic changes, and that an alternative degradation
pathway that does not involve FAAH may be present in the
granulosa cell. Indeed, recent evidence suggests that AEA can be
converted to a prostaglandin E2-ethanolamine through the actions
of cyclooxygenase 2, an enzyme that is expressed in the ovarian
granulosa cell [35] and which is under leptin control.
NAPE-PLD on the other hand was expressed in the
granulosa and theca cells of secondary, and tertiary follicles,
the corpus luteum and corpus albicans suggesting that AEA is
mainly produced from the granulosa of growing (secondary,
tertiary) follicles but not from oocytes. Since NAPE-PLD was
immunolocalised to the corpus luteum, and to a lesser extent
the corpus albicans, this also suggests that AEA is synthesised
by these from the two sources during the latter stages of the
menstrual cycle.
These observations suggest that AEA probably acts mostly on
CB2 receptors to produce its physiological actions in the ovary
and that it is degraded in the theca cells and corpora lutea and
albicantes. They also provide evidence that AEA is produced in
the human ovary and that this process is probably under
hormonal control as it is produced by growing follicles, the
corpus luteum and corpus albicans. The evidence thus suggests
that AEA affects the antral phase of folliculogenesis [36].
Nevertheless, recent evidence suggests that in the mouse, the
main actions of endocannabinoids are mediated through the
actions of the CB1 receptor causing an imbalance between E2
and P4 signalling [37]. The data presented herein are not at odds
with this observation as Wang et al., did not examine the
presence of the CB2 receptor, although they demonstrated that
CB2 was not involved through the use of a specific CB2
antagonist. These observations therefore highlight a differential
between murine and human ovarian physiology, as has been
previously observed with other markers of ovarian physiology
[38] and to our mind suggest that to really understand human
ovarian function the human not murine ovary needs to be
studied in more detail. Our volunteers from whom ovarian tissue
was obtained were approaching the end of their reproductive age
and therefore it would be interesting to replicate these studies in
younger women, to ensure that the effect of age on ovarian
physiology did not influence our observations.
The ovarian stimulation protocol used for IVF/ICSI women
causes the development of several follicles with a wide range of
sizes and at different developmental stages. The observed
increase in follicular fluid AEA concentrations with increased
follicle size and lower AEA concentrations in follicles from which
oocytes were not retrieved indicate that AEA is probably
involved in the maturation of follicles or the oocyte. Since
oocyte maturity is currently assessed subjectively by embryolo-
gists there is a need for a more objective method of assessment.
Although many potential biomarkers (estradiol and testosterone
(39), inhibin B [40], BMP-15 [41]) in follicular fluid have been
suggested to discriminate between mature and immature
oocytes, none of these are in current clinical practice. In this
regard, the ROC analysis demonstrating that a 1.09 nM
follicular fluid AEA level was predictive of mature oocytes in
77.14% of the cases is especially encouraging. Although this
study clearly indicates that follicular fluid AEA levels are
associated with both follicle and oocyte maturity, there are likely
to be a number of other factors that influence oocyte maturity
and quality in the local hormonal environment that we do not
know about [42]. It would be ideal to relate the follicular fluid
and plasma AEA levels with oocyte/embryo quality in women
with different causes of infertilit y ;h o w e v e r ,t h en u m b e r si nt h i s
study were too small for such sub-analyses. We believe that
follicular fluid AEA levels should be further investigated as a
possible biomarker for the assessment of oocyte maturity in
advanced reproductive technology procedures. This needs to be
done in conjunction with other biomarkers.
With regards to the embryo quality we did not find a significant
association between follicular fluid AEA concentrations and
Figure 6. Prediction of oocyte maturity from follicular fluid
AEA measurements. Panel a shows the follicular fluid AEA
concentrations from follicles that gave rise to mature and immature
oocytes during ICSI cycles. The long horizontal bar represents the mean
and the shorter bars the sem. Panel b shows a receiver-operating
characteristic curve (ROC) analysis for the prediction of the production
of mature oocytes from follicular AEA concentration. The sensitivity and
specificity relationship for measurements of anandamide in follicular
fluid is plotted. The optimum cut off point for the identification of
mature oocytes at 1.09 nM, provided a sensitivity of 72.2%,
(95CI=46.52% to 90.31%) and a specificity of 77.14% (95CI=59.86 to
89.58%) and likelihood ratio of 3.16. The area under the curve was
0.76860.067, (Mean6sem; 95%CI=0.63–0.89, P=0.001).
doi:10.1371/journal.pone.0004579.g006
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sperm quality are involved in determining embryo quality.
The fact that there was no significant difference between plasma
and follicular fluid AEA concentrations at the time of oocyte
collection suggests that systemic AEA concentrations reflect
ovarian AEA levels. Also, plasma AEA concentrations in women
undergoing IVF/ICSI at the time of oocyte collection were similar
to those found in women at ovulation in natural cycles [34] which
suggest that plasma AEA is involved in the ovulation process
whether it occurred naturally or was stimulated.
Conclusion
This study is a step forward in helping with the understanding of
the mechanisms of action of AEA in the human ovary. A better
understanding of the mechanism whereby AEA is produced in the
human ovary and how it affects oocyte maturity, whether nuclear
or cytoplasmic maturation, may help in the development of
strategies which may improve the outcome of ART. Furthermore,
there is a need to undertake larger studies to investigate the
potential use of follicular fluid AEA measurement as a predictor of
oocyte maturity.
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